Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Recruiting

Phase 1

Tumor-Treating Fields, Nivolumab, IpilimumabSingle Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Sponsor:

HonorHealth Research Institute

Code:

NCT05004025

Conditions

Uveal Melanoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Novocure Optune

Opdivo

Yervoy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-16. This information was provided to ClinicalTrials.gov by HonorHealth Research Institute on 2024-06-17.